Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380159 · ClinicalTrials.gov registry record · Phase 2
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00380159 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT00380159, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and meet the inclusion and exclusion criteria.
Interventions
- DRUG Lamivudine
- DRUG Emtricitabine
- DRUG Elvucitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00380159
The ClinicalTrials.gov registry entry for NCT00380159 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lamivudine is the first listed.
NCT00380159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00380159 about?
NCT00380159 is a clinical study titled "Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A". To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and meet the inclusion and exclusion criteria.
What is the current status of trial NCT00380159?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2006-09. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00380159?
The interventions under investigation include: Lamivudine (DRUG), Emtricitabine (DRUG), Elvucitabine (DRUG).
Who is sponsoring clinical trial NCT00380159?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.